FDA Division of Bioequivalence Director Dighe
Detailed to Office of Generic Drugs Director Roger Williams, MD, as his "Senior Advisor with specific responsibility for development of a number of critically important bioequivalence guidances," a Dec. 3 OGD memo states. The detail takes effect Jan. 4 and will extend at least four months. Williams wants to have a senior employee work fulltime on the guidances to make them available sooner to industry. Shrikant Dighe, PhD, will focus on guidelines regarding albuterol metered-dose inhalers, cholestyramine, general bioequivalence, immediate-release formulations, controlled-release formulations and non-fasting drug bioequivalence. Review Branch I Chief Agnes Wu, PhD, will serve as the bioequivalence division's acting director.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth